Selective Notch1 inhibition with a novel neutralizing monoclonal antibody developed in our laboratory not only exerts anti-tumor activity as a monotherapy, but importantly, boosts the therapeutic effects of anti-PD-1. The gene discussed is PDCD1; the disease is neoplasm.